Work

Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity

Year: 2024

Type: article

Abstract: Several ongoing trials are evaluating incretin-based therapies, including GLP-1 receptor agonists, for their effects on CKD and MASLD. These studies will offer insights into their potential for metabolic diseases in people with type 2 diabetes and obesity.

Source: Journal of Diabetes Investigation

DOI: 10.1111/jdi.14336

Authors: Jae Hyun Bae, Young Min Cho

Institutions: Seoul National University, Seoul National University Hospital

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,850